Steno Diabetes Center Copenhagen — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

10 Recruiting

1 Completed trials

5 Countries active

14 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase III: 1 Phase II: 6 Phase III/IV: 1 Phase IV: 4 Phase I (Other): 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic kidney disease 2 Monogenic diabetes 2

Top IMPs

FINERENONE 3 DASIGLUCAGON 1 EMPAGLIFLOZIN 1 GLUCAGON 1 SEMAGLUTIDE 1 TIRZEPATIDE 1

All trials

13 total

Clinical validation study of urinary clusterin and EGF in patients with chronic kidney disease Not authorised

2023-507449-27-00 Phase IV 5 countries
PLatelet aggregation and Aspirin low response in Type One Diabetes and the association with vascular damage and diabetic Nephropathy Pending

2024-520324-29-00 Phase II 1 country
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP) Recruiting

2025-524679-22-00 Phase II 1 country
The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglyc… Recruiting

2025-523996-45-00 Phase IV 1 country DASIGLUCAGON; GLUCAGON
Sotagliflozin for the treatment of post-bariatric hypoglycaemia: The ONSIDE study Recruiting

2023-509118-12-00 Phase II 1 country
Urinary proteomics to guide early intervention to prevent complications in type 2 diabetes – a feasibility study Recruiting

2024-518682-95-00 Phase IV 2 countries
CKD-bioMatch: A biomarker-targeted clinical trial to optimize treatment for patients with chronic kidney disease Recruiting

2023-507449-27-01 Phase IV 5 countries FINERENONE
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Recruiting

2024-517883-49-00 Phase I (Other) 1 country
The FibroCAN study Recruiting

2024-516597-30-00 Phase II 1 country FINERENONE
PLUTO - Prevention of CKD progression in type 1 diabetes with Long term Use of SGLTi avoiding kidney hypOxia Recruiting

2023-509450-55-01 Phase II 1 country
IDEAL-COR Recruiting

2023-505270-15-00 Phase III/IV 1 country TIRZEPATIDE
New treatments to reduce cardiovascular disease in type 1 diabetes Recruiting

2023-505794-32-04 Phase III 1 country FINERENONE; SEMAGLUTIDE
Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial Ended

2023-503760-17-00 Phase II 1 country EMPAGLIFLOZIN

Showing 1–13 of 13 trials

← All sponsors A–Z